title: The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients.
authors.forename: K
authors.initials: K
authors.lastname: Ohyashiki
authors.forename: Y
authors.initials: Y
authors.lastname: Aota
authors.forename: D
authors.initials: D
authors.lastname: Akahane
authors.forename: A
authors.initials: A
authors.lastname: Gotoh
authors.forename: K
authors.initials: K
authors.lastname: Miyazawa
authors.forename: Y
authors.initials: Y
authors.lastname: Kimura
authors.forename: J H
authors.initials: JH
authors.lastname: Ohyashiki
mesh_terms: D049109:Cell Proliferation; D006801:Humans; D053614:Janus Kinase 2; D020125:Mutation, Missense; D009190:Myelodysplastic Syndromes / Q000235:genetics* / Q000473:pathology*; D055728:Primary Myelofibrosis; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics*
chemical_list: D011518:Proto-Oncogene Proteins; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2